Glaxosmithkline, the UK's largest pharmaceuticals group, is to pay £220m to settle accusations that it fraudulently obtained a patent and pursued "sham litigation" to block a rival arthritis pill.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results